Dr. Bissonnette, Indero’s Founder and Executive Chairman, alongside with peers, has authored the following abstract presented during this morning’s Late Breaking session at AAD:
Tapinarof Cream 1% Once Daily: Maintenance of Low Disease Activity Including Pruritus Through End of the Treatment-free Interval in a Long-term Extension Trial in Patients Down to 2 Years of Age with Atopic Dermatitis
Indero is proud of its role in improving the lives of patients with skin diseases.